AUTHOR LOGIN Close
Please enter author credentials to view Author Manual
Username:
Password:  
   
for New Author Registration
JAYPEE JOURNALS
International Scientific Journals from Jaypee
IndexCopernicus Value: 80.23
Home Instructions Editorial Board Current Issue Pubmed Archives Subscription Advertisement Contact Us
 
LOGIN  
Username: Password:
 
New Author Registration | Forgot Password ?
 
 
 
Most Downloaded Articles of the Journal
 
 
List of All Articles
1.  HYPERTENSION AND NEUROGENIC IMPACT
Hypertension and Ischemic Stroke
Sudhir Kumar
[Year:2016] [Month:January-March] [Volume:2 ] [Number:1] [Pages:53] [Pages No:39-43] [No of Hits : 837]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0028 | FREE

ABSTRACT

Stroke is among the leading causes of death and disability worldwide. Ischemic stroke is 3 to 4 times more common than hemorrhagic stroke. Hypertension is the commonest risk factor for ischemic stroke, in addition to diabetes mellitus, dyslipidemia and smoking. Blood pressure (BP) lowering with appropriate antihypertensive agents would lead to reduction of first ever stroke as well as recurrent strokes. This article discusses the epidemiology of strokes in India, role of hypertension in ischemic stroke causation and its recurrence; BP targets to be achieved, and the preferred antihypertensive agents. In addition, management of hypertension in the setting of acute ischemic stroke is also discussed. Blood pressure lowering is generally avoided within the first 24 hours after acute ischemic stroke. Proper BP management is one of the keys to ensure better outcomes in acute stroke setting.

Keywords: Antihyper tensive agents, Epidemiology, Hypertension, India, Ischemic, Prevention, Risk factor, Stroke, Stroke recurrence, Target BP.

How to cite this article: Kumar S. Hypertension and Ischemic Stroke. Hypertens J 2016;2(1):39-43.

Source of support: Nil

Conflict of interest: None

 
2.  Hemodynamics of hypertension
Central Aortic Blood Pressure and Pulse Wave Velocity as Additional Markers in Patients with Hypertension
Ravi R Kasliwal, Kushagra Mahansaria, Manish Bansal
[Year:2015] [Month:October-December] [Volume:1 ] [Number:2] [Pages:57] [Pages No:73-82] [No of Hits : 796]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0013 | FREE

ABSTRACT

Arterial stiffness is a pathological manifestation of cumulative vascular damage resulting from various known and unknown vascular risk factors. Central aortic pressure and pulse wave velocity are the two most commonly used and the most informative non-invasive measures of arterial stiffness. Numerous studies have documented incremental value of these measures in a variety of clinical conditions, most notably, hypertension. In hypertensive subjects, assessment of arterial stiffness not only provides incremental information about vascular risk, it also helps in guiding therapeutic decision making and serves as a tool for monitoring response to antihypertensive therapy.

Keywords: Arterial stiffness, Arteriosclerosis, Subclinical atherosclerosis, Vascular damage.

How to cite this article: Kasliwal RR, Mahansaria K, Bansal M. Central Aortic Blood Pressure and Pulse Wave Velocity as Additional Markers in Patients with Hypertension. Hypertens J 2015;1(2):73-82.

Source of support: Nil

Conflict of interest: None

 
3.  Status Report
Hypertension as a Public Health Problem in India
Rajeev Gupta
[Year:2015] [Month:July-September] [Volume:1 ] [Number:1] [Pages:61] [Pages No:1-3] [No of Hits : 693]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0001 | FREE

ABSTRACT

Hypertension is the most important risk factor for global morbidity and mortality. It has assumed epidemic proportions in India with an estimated 100 million patients. In recent decades, the disease is increasing more rapidly in rural than in urban population. Status of hypertension treatment and control is dismal in India with about a third of patients on treatment and only 20% controlled. Innovative system-based strategies using a combination of public health approaches and physician led clinic-based management are required to prevent premature cardiovascular disease burden due to hypertension.

Keywords: Cardiovascular disease, Hypertension epidemiology, Public health approach, Risk factors.

How to cite this article: Gupta R. Hypertension as a Public Health Problem in India. Hypertens J 2015;1(1):1-3.

Source of support: Nil

Conflict of interest: None

 
4.  Review Article
Risk Assessment in Young Hypertensives
Niteen V Deshpande
[Year:2015] [Month:October-December] [Volume:1 ] [Number:2] [Pages:57] [Pages No:94-99] [No of Hits : 562]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0016 | FREE

ABSTRACT

Hypertension (HT) in young (< 40 years) is a significant problem in India. Preventing cardiovascular disease in these young hypertensives is a major challenge as management strategies for young hypertensives are not very clear. Risk assessment in young hypertensives is also limited as most of the risk assessment algorithms apply to population above 40 years. Unfortunately, we do not have a specific algorithm for Indian patients. The algorithm given by Joint British Societies (JBS-3) appears to be most suited for risk assessment in young Indian Hypertensive individuals. Additionally, multiple newer markers may be needed to understand the cardiovascular risk completely in the young hypertensive population.

Keywords: Cardiovascular risk assessment, Risk markers, Young hypertensives.

How to cite this article: Deshpande NV. Risk Assessment in Young Hypertensives. Hypertens J 2015;1(2):94-99.

Source of support: Nil

Conflict of interest: None

 
5.  Lifestyle changes
Yoga and Hypertension
Subhash Chandra Manchanda, Kushal Madan
[Year:2015] [Month:July-September] [Volume:1 ] [Number:1] [Pages:61] [Pages No:28-33] [No of Hits : 515]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0005 | FREE

ABSTRACT

Hypertension is a major public health problem and is an important risk factor for stroke, coronary heart disease and renal failure. The blood pressure is not well controlled with drug therapy in large number of individuals, especially in the developing countries. There is a need for less expensive nonpharmacological alternative methods to control blood pressure. Yoga may be such cost-effective alternative. Several uncontrolled and randomized control trials have evaluated short- and long-term effects of yoga/meditation-based techniques in prehypertension and mild hypertension. Though, the results are mixed and there are several methodological limitations in reported studies, majority of studies demonstrate a modest decrease in both systolic and diastolic blood pressure. This modest decrease may significantly decrease the stroke mortality and coronary heart disease in general population. A recent scientific statement of American Heart Association also suggests that it is reasonable for all individuals with blood pressure levels more than 120/80 mm Hg to consider alternative approaches like transcendental medication as adjunct method to lower blood pressure.

Keywords: Meditation, Prehypertension, Psychosocial stress, Yoga.

How to cite this article: Manchanda SC, Madan K. Yoga and Hypertension. Hypertens J 2015;1(1):28-33.

Source of support: Nil

Conflict of interest: None

 
6.  SECONDARY HYPERTENSION
Severe Paroxysmal Hypertension: Pseudopheochromocytoma
Samuel J Mann
[Year:2016] [Month:April-June] [Volume:2 ] [Number:2] [Pages:53] [Pages No:96-102] [No of Hits : 444]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0038 | FREE

ABSTRACT

Paroxysmal hypertension always engenders a search for a catecholamine-secreting pheochromocytoma (pheo). However, in 98% of cases, a pheo is not found, and the cause and management of the paroxysmal hypertension have remained a largely unstudied mystery. This review presents an approach to understanding and successfully treating this disorder, which is increasingly known as “pseudopheochromocytoma,” or “pseudopheo.” Patients with this disorder experience sudden, unprovoked, and symptomatic blood pressure elevations that are likely linked to stimulation of the sympathetic nervous system. Psychological characteristics associated with this disorder suggest a basis in repressed emotion related either to prior emotional trauma or to a repressive (nonemotional) coping style. Based on this understanding, successful intervention is possible in most of the cases. Hypertensive paroxysms can usually be managed acutely with an anxiolytic agent, such as alprazolam, an antihypertensive agent that targets the sympathetic nervous system, such as clonidine, or a combination of the two. Severe paroxysms may require an intravenous agent, such as labetalol or nitroprusside. In patients with severe and/or frequent paroxysms, recurrence of paroxysms can be prevented in most of the cases with an antidepressant drug. The importance of reassurance cannot be overstated. The possible role of psychotherapeutic intervention requires further study. Fortunately, with appropriately selected intervention, paroxysms can be effectively treated or eliminated in most patients.

Keywords: Catecholamines, Hypertension, Labile hypertension, Paroxysmal hypertension, Pheochromocytoma, Pseudopheochromocytoma.

How to cite this article: Mann SJ. Severe Paroxysmal Hypertension: Pseudopheochromocytoma. Hypertens J 2016;2(2):96-102.

Source of support: Nil

Conflict of interest: None

 
7.  HYPERTENSION AND THE KIDNEY
Hypertension in Patients with Chronic Kidney Disease
P Vijay Varma, M Rajasekara Chakravarthi, G Jyothsna
[Year:2016] [Month:January-March] [Volume:2 ] [Number:1] [Pages:53] [Pages No:28-34] [No of Hits : 380]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0026 | FREE

ABSTRACT

The prevalence of hypertension in chronic kidney disease (CKD) patients exceeds that of the general population. Uncontrolled hypertension plays a significant role in progression to end stage renal disease and results in increased cardiovascular morbidity and mortality. A complex interplay between various pathophysiologic mechanisms is responsible for the development of hypertension in this patient population. The major factors being extracellular volume overload, increased endothelin-1 release and excess renin-angiotensin-aldosterone system and sympathetic nervous system activity. Dietary and lifestyle modifications have synergistic effects to drug therapy in the control of hypertension. There is no single blood pressure target that is optimal for all CKD patients. It is important to individualize the treatment depending on age, the severity of albuminuria, and comorbidities. Drugs blocking the renin-angiotensin-aldosterone system are the recommended first-line antihypertensive agents for most CKD patients. Intradialytic hypertension may be prevented by individualizing the dialysis prescription and using nondialyzable antihypertensives. New onset of hypertension in the elderly or new onset of difficult to control hypertension in a previously well controlled hypertensive patient should prompt the work up for atherosclerotic renal vascular disease.

Keywords: Aldosterone, Angiotensin, Chronic, Hypertension, Kidney, Renin.

How to cite this article: Varma PV, Chakravarthi MR, Jyothsna G. Hypertension in Patients with Chronic Kidney Disease. Hypertens J 2016;2(1):28-34.

Source of support: Nil

Conflict of interest: None

 
8.  PATHOPHYSIOLOGY OF HYPERTENSION
Metabolic Syndrome in the Indian Population: Public Health Implications
PP Mohanan
[Year:2016] [Month:January-March] [Volume:2 ] [Number:1] [Pages:53] [Pages No:1-6] [No of Hits : 378]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0021 | FREE

ABSTRACT

Metabolic syndrome (MS) is now being increasing recognized as an emerging threat which will invade desktops of public health policy planners in the decades to come. The clusters which make this syndrome and its etiopathogenesis will keep getting varied in different ethnic populations, regions and countries. Factors like migration, socioeconomic status, lifestyle, nutrition habits play important role. Therefore, research in MS provides an interdisciplinary forum to explore the pathophysiology, recognition, and treatment of the cluster of conditions associated with the evolving entity of MS.

Keywords: Atherosclerotic, Dyslipidemia, Intramyocellular lipids.

How to cite this article: Mohanan PP. Metabolic Syndrome in the Indian Population: Public Health Implications. Hypertens J 2016;2(1):1-6.

Source of support: Nil

Conflict of interest: None

 
9.  NEWER THERAPEUTIC INSIGHT
Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach
Prabhash C Manoria, Pankaj Manoria, Nidhi Mishra
[Year:2016] [Month:July-September] [Volume:2 ] [Number:3] [Pages:80] [Pages No:145-152] [No of Hits : 319]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0047 | FREE

ABSTRACT

A new revolution has begun in the management of chronic heart failure with reduced ejection fraction (CHFrEF). The new blockbuster angiotensin receptor neprilysin inhibitor (ARNI/LCZ696) has evoked a new concept of multisystem neurohormonal modulation, and indeed, this has shown an additional decrease in cardiovascular (CV) mortality on top of all standard evidence-based drugs for the treatment of CHFrEF, i.e., angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), beta blockers, and mineralocorticoid receptor antagonists (MRAs) coupled with diuretics. LCZ696 has two drugs, ARB valsartan and neprilysin inhibitor sacubitril, fused in a molecular complex. The combination provides a dual strategy of combating neurohormonal activation in heart failure (HF), i.e., by blocking harmful effect of renin-angiotensinaldosterone system by valsartan and simultaneously increasing the activation of vasoactive peptides by inhibiting neprilysin. It was evaluated in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, which produced a statistically significant dramatic reduction of 20% in the primary end point of a composite of death from CV cause and hospitalization for HF. The combination is well tolerated, and side effects are minimal. LCZ696 has been approved for clinical use and has been endorsed by the European Society of Cardiology and American College of Cardiology/American Heart Association/ Heart Failure Society of America 2016 guidelines. What is very exciting is that it has emerged as a replacement therapy for class I A drug (ACE/ARB) rather than as a mere add-on therapy, which is the usual story with any new drug. The drug is likely to be available in India in the near future.

Keywords: Angiotensin receptor neprilysin inhibitor review, Heart failure with reduced ejection fraction, PARADIGM-HF.

How to cite this article: Manoria PC, Manoria P, Mishra N. Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach. Hypertens J 2016;2(3):145-152.

Source of support: Nil

Conflict of interest: None

 
10.  PATHOPHYSIOLOGY OF HYPERTENSION
White Crystals Controversy: Sugar rather than Salt as the Etiology of Hypertension
Tiny Nair
[Year:2016] [Month:January-March] [Volume:2 ] [Number:1] [Pages:53] [Pages No:7-9] [No of Hits : 309]
Full Text PDF | Abstract | DOI : 10.5005/jp-journals-10043-0022 | FREE

ABSTRACT

Traditionally, salt intake is linked to hypertension, and salt restriction forms the foundation for “lifestyle” management of hypertension. Despite an increase in incidence of hypertension in the population, data did not show any increase in salt intake over longer time frame. Increased intake of processed food amounts to increase in sugars especially fructose. Rampant and excessive commercial use of high fructose corn syrup in ready-to-eat “fast” food results in hypertension by various mechanisms. This interesting shift of concept of white crystals from salt to sugar is reviewed in this commentary.

Keywords: High fructose corn syrup, Hypertension, Salt, Sugar.

How to cite this article: Nair T. White Crystals Controversy: Sugar rather than Salt as the Etiology of Hypertension. Hypertens J 2016;2(1):7-9.

Source of support: Nil

Conflict of interest: None

 
   Previous |  Next  
Logo
 
     
 
© Jaypee Brothers Medical Publishers (P) Ltd.
logo